Difference between revisions of "CARB-X"
m (Text replacement - "nonprofit" to "nonprofit") |
(logo, expand) |
||
| Line 1: | Line 1: | ||
{{group | {{group | ||
|wikipedia=https://en.wikipedia.org/wiki/CARB-X | |wikipedia=https://en.wikipedia.org/wiki/CARB-X | ||
| + | |twitter=https://twitter.com/carb_x?lang=ru | ||
|sourcewatch= | |sourcewatch= | ||
| − | |constitutes= | + | |constitutes=public-private partnership |
| − | + | |start=July 28, 2016 | |
| − | |start= | + | |description=A globalpartnership focused on [[antibacterial products]], financed by the super-spooky [[BARDA]] and the [[Gates Foundation]]. |
| − | |description= | + | |headquarters=Boston,Boston University,Massachusetts,USA |
| − | |headquarters=Boston University,Massachusetts,USA | ||
|interests=Antimicrobial resistance,antibiotics,antimicrobials | |interests=Antimicrobial resistance,antibiotics,antimicrobials | ||
|website=https://carb-x.org/ | |website=https://carb-x.org/ | ||
|founders= | |founders= | ||
| + | |logo=CARB-X logo.png | ||
| + | |titular_logo=1 | ||
|num_staff= | |num_staff= | ||
| − | |members= | + | |sponsors=Doherty Institute,University of Maryland |
| + | |members=Kevin Outterson,Richard Alm, Jane Ambler,Emma Back,Mike Barbachyn,Greg Basarab,Tim Blizzard,Robert Bonomo (CARB-X),Keith Bostian,Helen Boucher,Tom Boyles,Patricia Bradford,Andrew Camilli,Joe Campbell,Chris Chengelis,David Christ,David Clarke,Bob Clay,David Cook,Lloyd Czaplewski,Peter Dailey,Aaron Dane,Shampa Das,Melnick Dave,Joe Devito,Sabine Dittrich,Alice Erwin,Marta Fernandez Suarez,Phil Fernsten,Patrick Flume,Anthony Ford-Hutchinson,Jo Fothergill,Francois Franceschi,Carrie Furr,Humphrey Gardner,Debbie Goff,Mark Goldberg,Herman Goossens,Howard Haimes,Kim Hanson,Herb Harwell,David Heilman,Carla Hoitink,Richard Hotchkiss,David Hughes,Romney Humphries,Deb Hung,Joe Iaconis,Rick Jack,Namita Jaggi,Zoltan Kanyo,Keith Kaye,Cassandra Kelly-Cirino,Jacqueline Kirchner,Jeff Klausner,Ajay Kumar,Pascal Lavoie,Mathew Lo,Camille Locht,Tom Lowery,Patrick Lukulay,Nada Malou,Helen Marshall,Laura Martin,Marielena Mata,Bob McLaughin,Helen McShane,Marc Mendelson,Paul Miller,Linda Miller,Nel Moore,Marshall Morningstar,Ian Morrissey,Larry Mortin, | ||
}} | }} | ||
| − | '''Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator''' ('''CARB-X''') is a global [[nonprofit]] partnership focused on supporting the development of new antibacterial products. | + | '''Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator''' ('''CARB-X''') is a global [[nonprofit]] partnership focused on supporting the development of new [[antibacterial products]], <ref>https://web.archive.org/web/20160802054526/http://www.bu.edu:80/law/faculty-scholarship/carb-x/</ref> financed by the super-spooky [[BARDA]] and the [[Gates Foundation]]. |
| + | ==History== | ||
| + | CARB-X launched July 28, [[2016]] as one of the world's largest [[public-private partnership]]s to accelerate global [[antibacterial]] innovation, including drugs, [[vaccines]], rapid [[diagnostics]] and devices. CARB-X aims to invest up to $450 million over five years with the goal of accelerating the preclinical discovery and development of at least 20 new antibacterial products.<ref name=injects>https://carb-x.org/carb-x-news/carb-x-injects-up-to-48-million-to-accelerate-first-powered-by-carb-x-portfolio-of-drug-development-projects-to-tackle-antibiotic-resistance/</ref> | ||
==Activities== | ==Activities== | ||
"The CARB-X initiative plays an important role in [[BARDA]]'s goal to catalyze the early stage development pipeline and enhance our national health security preparedness. CARB-X allows BARDA to tap into a partnership of co-funders, accelerators, and innovators who are pushing critical [[novel antimicrobials]] from discovery to the market to address the public health and national security concerns of [[antibiotic resistant bacteria]]."<ref>https://carb-x.org/partners/funding-partners/</ref> | "The CARB-X initiative plays an important role in [[BARDA]]'s goal to catalyze the early stage development pipeline and enhance our national health security preparedness. CARB-X allows BARDA to tap into a partnership of co-funders, accelerators, and innovators who are pushing critical [[novel antimicrobials]] from discovery to the market to address the public health and national security concerns of [[antibiotic resistant bacteria]]."<ref>https://carb-x.org/partners/funding-partners/</ref> | ||
| + | |||
| + | In May 2021, it funded [[SNIPR BIOME]], "a leading [[CRISPR]] and [[microbiome]] biotech company" incorporated in [[Copenhagen, Denmark]], with US $3.9 million. The company applies its CRISPR technologies to selectively target [[microbial pathogens]] and remodelling the [[microbiome]].<ref>https://carb-x.org/carb-x-news/carb-x-is-funding-snipr-biome-to-develop-a-crispr-engineered-drug-to-eradicate-escherichia-coli-e-coli-bacteria-in-cancer-patients-to-prevent-deadly-infections/</ref> | ||
==Board members== | ==Board members== | ||
| − | The Joint Oversight Board and Advisory Board members are | + | The Joint Oversight Board and Advisory Board members are not discloses.<ref>https://carb-x.org/about/advisory-board</ref> The members are "a snapshot of their subject matter [[experts]]" as of November 2024.<ref>https://carb-x.org/about/advisory-board/</ref> [[Kevin Outterson]], Executive Director of CARB-X in 2016, is a Professor of Law at Boston University.<ref name=injects/><ref>https://archive.is/9o8Zp</ref> |
==Finances== | ==Finances== | ||
| − | Many of the usual suspects.<ref>https://carb-x.org/partners/funding-partners/</ref> | + | Many of the usual suspects, including the spooky [[BARDA]], the [[Gates Foundation]], and [[Wellcome Trust]]. Other funders include [[Germany's Federal Ministry of Education and Research]] (BMBF); the [[United Kingdom's Department of Health and Social Care]](DHSC), through its [[Global Antimicrobial Resistance Innovation Fund]] (GAMRIF), the [[Public Health Agency of Canada]] (PHAC), the [[Novo Nordisk Foundation]]; and the [[NIAID|Unites States' National Institute of Allergy and Infectious Diseases]] (NIAID), part of the [[National Institutes of Health]] (NIH).<ref>https://carb-x.org/partners/funding-partners/</ref> |
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
| − | |||
Latest revision as of 05:28, 19 November 2024
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global nonprofit partnership focused on supporting the development of new antibacterial products, [1] financed by the super-spooky BARDA and the Gates Foundation.
History
CARB-X launched July 28, 2016 as one of the world's largest public-private partnerships to accelerate global antibacterial innovation, including drugs, vaccines, rapid diagnostics and devices. CARB-X aims to invest up to $450 million over five years with the goal of accelerating the preclinical discovery and development of at least 20 new antibacterial products.[2]
Activities
"The CARB-X initiative plays an important role in BARDA's goal to catalyze the early stage development pipeline and enhance our national health security preparedness. CARB-X allows BARDA to tap into a partnership of co-funders, accelerators, and innovators who are pushing critical novel antimicrobials from discovery to the market to address the public health and national security concerns of antibiotic resistant bacteria."[3]
In May 2021, it funded SNIPR BIOME, "a leading CRISPR and microbiome biotech company" incorporated in Copenhagen, Denmark, with US $3.9 million. The company applies its CRISPR technologies to selectively target microbial pathogens and remodelling the microbiome.[4]
Board members
The Joint Oversight Board and Advisory Board members are not discloses.[5] The members are "a snapshot of their subject matter experts" as of November 2024.[6] Kevin Outterson, Executive Director of CARB-X in 2016, is a Professor of Law at Boston University.[2][7]
Finances
Many of the usual suspects, including the spooky BARDA, the Gates Foundation, and Wellcome Trust. Other funders include Germany's Federal Ministry of Education and Research (BMBF); the United Kingdom's Department of Health and Social Care(DHSC), through its Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Public Health Agency of Canada (PHAC), the Novo Nordisk Foundation; and the Unites States' National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).[8]
Known member
1 of the 74 of the members already have pages here:
| Member | Description |
|---|---|
| Debra Goff | US doctor |
Sponsors
| Event | Description |
|---|---|
| BARDA | Responsible for bioterrorism "medical countermeasures" (i.e. the actual biological weapons, like "vaccines") |
| Bill & Melinda Gates Foundation | Very influential and rich foundation established to take leadership of global health. |
| National Institute of Allergy and Infectious Diseases | |
| Wellcome Trust | 4th wealthiest charitable foundation in the world |
References
- ↑ https://web.archive.org/web/20160802054526/http://www.bu.edu:80/law/faculty-scholarship/carb-x/
- ↑ a b https://carb-x.org/carb-x-news/carb-x-injects-up-to-48-million-to-accelerate-first-powered-by-carb-x-portfolio-of-drug-development-projects-to-tackle-antibiotic-resistance/
- ↑ https://carb-x.org/partners/funding-partners/
- ↑ https://carb-x.org/carb-x-news/carb-x-is-funding-snipr-biome-to-develop-a-crispr-engineered-drug-to-eradicate-escherichia-coli-e-coli-bacteria-in-cancer-patients-to-prevent-deadly-infections/
- ↑ https://carb-x.org/about/advisory-board
- ↑ https://carb-x.org/about/advisory-board/
- ↑ https://archive.is/9o8Zp
- ↑ https://carb-x.org/partners/funding-partners/
